A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

Author： Gelmon K.   Hirte H.   Fisher B.   Walsh W.   Ptaszynski M.   Hamilton M.   Onetto N.   Eisenhauer E.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.22, Iss.3, 2004-08, pp. : 263-275

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

By Johnson Peter   Geldart Thomas   Fumoleau Pierre   Pinel Marie-Claire   Nguyen Laurent   Judson Ian  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 223-231

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

By Royce Melanie E.   Rowinsky Eric K.   Hoff Paulo M.   Coyle John   DeJager Robert   Pazdur Richard   Saltz Leonard B.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

By Gelmon Karen   Belanger Karl   Soulieres Denis   Britten Carolyn   Chia Stephen   Charpentier Danielle   Chi Kim   Powers Jean   Walsh Wendy   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 445-453

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

By Ramanathan Ramesh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1591-1596

Springer Publishing Company

Access to resources Recommend Favorite